Strategies for dealing with reactive intermediates in drug discovery and development

Current Opinion in Drug Discovery and Development

Volumn 7, Issue 1, 2004, Pages 126-136

  Nassar, Alaa Eldin F ^a   Lopez Anaya, Arturo ^b  

^a PFIZER INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Covalent binding; Enzyme inhibition; Hypotheses for idiosyncratic reactions; Idiosyncratic drug reactions (IDRs); In silico methods; In vitro assays; Reactive intermediates; Trapping reactive intermediates

Indexed keywords

CHEMICAL REACTION; COVALENT BOND; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; METABOLITE; REVIEW; TOXICITY; ANIMAL; CHEMISTRY; DRUG DESIGN; DRUG HYPERSENSITIVITY; HUMAN; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; PHARMACOKINETICS; PROTEIN BINDING;

DRUG; FREE RADICAL;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG HYPERSENSITIVITY; FREE RADICALS; HUMANS; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING;

EID: 2942593914     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Bakke OM, Warden WM, Lasagna L: Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety. Clin Pharmacol Ther (1984) 35(5):559-567. This paper compares the number of new chemical entities and new biological entities approved for marketing during the period between 1964 and 1983 that were subsequently discontinued.
2. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L: Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther (1995) 58(1):108-117. This paper compares the number of new chemical entities and new biological entities approved for marketing during the period between 1974 and 1993 that were subsequently discontinued.
3. Uetrecht JP: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab (2000) 1(2):133-141. This review suggests that the development of an accurate method to predict which candidates are likely to cause IDRs will be difficult but the subsequent gains will be enormous.
4. Iverson S, Zahid N, Uetrecht JP: Predicting drug-induced agranulocytosis: Characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact (2002) 142(1-2) 175-199.
5. Uetrecht JP: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Disc Today (2003) 8(18):832-837.
6. Liu ZC, Uetrecht JP: Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to cells. J Pharmacol Exp Ther (1995) 275(3):1476-1483.
7. Li AP: A review of the common properties of drugs with idiosyncratic hepatoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact (2002) 142(1-2):7-23.
8. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK: Adverse drug reactions. Br Med J (1998) 316 (7140):1295-1298. An overview on the status of knowledge of ADRs based on a database search between 1981 and 1997, and the complexity of some unusual ADRs are briefly described.
9. Lasser KE, Alten PD, Wodhanfler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc (2002) 287(17):2215-2220.
10. Pohl LR, Satoh H, Christ DD, Kenna JG: The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol (1988) 28:367-387.
11. Ballet F: Hepatoxicity in drug development: Detection, significance and solutions. J Hepatol (1997) 26(Suppl 2):26-36.
12. Klaassen CD, Eaton DL: Principal of toxicology. In: Casarett and Doull's Toxicology. The Basic Science of Poisons, 4th Edition. Amour MA, Doull J, Klaassen CD (Eds), Pergamon Press, New York, NY, USA (1991):12-49.
13. Uetrecht J: Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discovery Dev (2001) 4(1)55-59.
14. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol (2000) 32(1):56-67.
15. Matzinger P: The danger model: A renewed sense of self. Science (2002) 296(5566):301-305. The danger model is described (see also reference [16••]).
16. Matzinger P: Essay 1: The danger model in its historical context. Scand J Immunol (2001) 54(1-2):4-9. The danger model and its history is described (see also reference [15••]).
17. Matzinger P: An innate sense of danger. Semin Immunol (1998) 10(5):399-415. The differences between innate immunity and the danger model are described.
18. Janeway CA Jr: How the immune system protects the host from infection. Microbes Infect (2001) 3(13):1167-1171. Highlights the criteria that allow the immune system to rid the body of pathogens (using destructive effector mechanisms) without destroying the host.
19. Anderson CC, Matzinger P: Danger: The view from the bottom of the cliff. Semin Immunol (2000) 12(3):231-238.
20. Pichler WJ: Pharmacological interaction with drugs with antigen-specific immune receptor: The P-I concept. Curr Opin Allergy Clin Immunol (2002) 2(4):301-305.
21. Harlan DM, Metzger DW, Karp CL, Matzinger P, Munn DH, Ransohoff RM: Immune response to engineered tissues and cells: Breakout session summary. Ann NY Acad Sci (2002) 961:350-351.
22. Pirmohamed M, Park BK: Metabolic models of cytotoxicity. In: Handbook of Drug Metabolism. TF Woolt (Ed), Marcel Dekker Inc, New York, NY, USA (1999):443-476.
23. Greene N: Computer systems for the prediction of toxicity: An update. Adv Drug Deliv Rev (2002) 54(3):417-431.
24. Richard AM: Structure-based methods for predicting mutagenicity and carcinogenicity: Are we there yet? Mutat Res (1998) 400(1-2):493-507.
25. Judson PN, Vessey JD: A comprehensive approach to argumentation. J Chem Inf Comput Sci (2003) 43(5):1356-1363. This paper describes a reasoning model based on the logic of argumentation.
26. Judson PN, Marchant CA, Vessey JD: Using argumentation for absolute reasoning about the potential toxicity of chemicals. J Chem Inf Comput Sci (2003) 43(5):1364-1370. The reasoning model based on the logic of argumentation is used for the prediction of the toxicity of chemicals.
27. Cashman JR: Human flavin-containing monooxygenase: Substrate specificity and role in drug metabolism. Curr Drug Metab (2000) 1(2):181-191.
28. Cashman JR: The role of flavin-containing monooxygenases in drug metabolism and development. Curr Opin Drug Discovery Dev (2003) 6(4):486-493.
29. Beedham C: The role of non-P450 enzymes in drug oxidation. Pharm World Sci (1997) 19(6):255-253.
30. Mattocks AR, Legg RF, Jukes R: Trapping of short-lived electrophilic metabolites of pyrrolizidine alkaloids escaping from perfused rat liver. Toxicol Lett (1990) 54(1):93-99.
31. Mehta JR, Ludlum DB: Trapping of DNA-reactive metabolites of therapeutic or carcinogenic agents by carbon-14-labeled synthetic polynucleotides. Cancer Res (1982) 42(8):2996-2999.
32. Lin EL, Mattox JK, Pereira MA: Glutathione plus cytosol- and microsome-mediated binding of 1,2-dichloroethane to polynucleotides. Toxicol Appl Pharmacol (1985) 78(3):428-435.
33. Grilli S, Rocchi P, Prodi G: Non-enzymatic and microsome-dependent binding of poly-cyclic hydrocarbons to DNA and polynucleotides. Chem Biol Interact (1975) 11(5):351-363.
34. Mathews RA, Stohrer G: Carcinogenic purine N-oxide ester modifies covalently all common bases in polynucleotides. Chem Biol Interact (1980) 29(1):57-66.
35. Chen WG, Zhang C, Avery MJ, Fouda HG: Reactive metabolite screen for reducing candidate attrition in drug discovery. In: Biological Reactive Intermediates VI. Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases. Dansetter PM, Snyder R, Delaforge M, Gibson GG, Greim H, Jollow DJ, Monks TJ, Sipes IG (Eds), Kluwer Academic/Plenum Press, New York, NY, USA (2001):521-524. This is one of the few articles that describes the use of LC-MS for screening reactive metabolites.
36. O'Donovan DJ, Fernandes C.J: Mitochondrial glutathione and oxidative stress: Implications for pulmonary oxygen toxicity in premature infants. Mol Genet Metab (2000) 71 (1-2):352-358.
37. Boelsterli UA: Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr Drug Metab (2002) 3(4):439-450.
38. *.. Free Radic Biol Med (1999) 27(3-4):329-333.
39. Pritsos CA, Constantinides PP, Tritton TR, Heimbrook DC, Sartorelli AC: Use of high-performance liquid chromatography to detect hydroxyl and superoxide radicals generated from mitomycin C. Anal Biochem (1985) 150(2):294-299.
40. Sanders SP, Bassett DJ, Harrison SJ, Pearse D, Zweier JL, Becker PM: Measurements of free radicals in isolated, ischemic lungs and lung mitochondria. Lung (2000) 178(2):105-118.
41. 14C-sodium cyanide during microsomal oxidation. Adv Exp Med Biol (1991) 283:657-664.
42. Wells PG, Zubovits JT, Wong ST, Molinari LM, Ali S: Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and α-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetase. Toxicol Appl Pharmacol (1989) 97(2):192-202.
43. Zhao Z, Koeplinger KA, Padbury GE, Hauer MJ, Bundy GL, Banitt LS, Schwartz TM, Zimmermann DC, Harbach PR, Mayo JK, Aaron CS: Bioactivation of 6,7-dimethyl-2,4-di-1-pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) to reactive intermediates that bind covalentty to macromolecules and produce genotoxicity. Chem Res Toxicol (1996) 9(8):1230-1239.
44. Zhao Z, Koeplinger KA, Bundy GL, Banitt LS, Padbury GE, Hauer MJ, Sanders PE: In vitro and in vivo biotransformation of 6,7-dimethyl-2,4-di-1- pyrrolidinyl-7H-pyrrolo[2,3-d]pyrimidine (U-89843) in the rat. Drug Metab Dispos (1996) 24(2):187-198.
45. Uetrecht JP: Reactive metabolites and agranulocytosis. Eur J Haematol (1996) 60(Suppl):83-88.
46. Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET: Predictability of the covalent binding of acidic drugs in man. Life Sci (1993) 53(8):PL141-PL146.
47. Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H: Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos (1999) 27(10):1143-1149.
48. Li C, Olurinde MO, Hodges LM, Grillo MP, Benet LZ: Covalent binding of 2-phenylpropionyl-S-acyl-CoA thioester to tissue proteins in vitro. Drug Metab Dispos (2003) 31(6):727-730.
49. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J: Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther (2003) 74(2):186-194.
50. Irving CC: Influence of the aryl group on the reaction of glucuronides of N-arylacethydroxamic acids with polynucleotides. Cancer Res (1977) 37(2):524-528.
51. Sallustio B, Sabordo L, Evans AM, Nation RL: Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab (2000) 1(2):163-180.
52. Sallustio BC, Fairchild BA, Pannall PR: Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-β-D-glucuronide. Drug Metab Dispos (1997) 25(1):55-60.
53. Boocock DJ, Maggs JL, Brown K, White IN, Park BK: Major interspecies differences in the rates of O-sulphonation and O-glucuronylation of α-hydroxytamoxifen in vitro: A metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis (2000) 97(10): 1851-1858.
54. Ding A, Zia-Amimosseini P, McDonagh AF, Burlingame AL, Benet LZ: Reactivity of tolmetin glucuronide with human serum albumin: Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab Dispos (1995) 23(3):369-376.
55. Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, Catinot R, Ballet F, Mansuy D. Beaune PH: Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: Comparison with two hepatotoxic drugs. Chem Res Toxicol (1994) 7(3):434-442.
56. Samuel K, Yin W, Steams RA, Tang YS, Chaudhary AG, Jewell JP, Lanza T Jr, Lin LS, Hagmann WK, Evans DC, Kumar S: Addressing the metabolic activation potential of new leads in drug discovery: A case study using ion trap mass spectrometry and tritium labeling techniques. J Mass Spectrom (2003) 38(2):211-221.
57. Rodriguez RJ, Buckholz CJ: Hepatotoxicity of ketoconazole in Sprague-Dawley rats: Glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding. Xenobiotica (2003) 33(4):429-441.
58. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Tox (2004): in press. An excellent paper that discussess bioactivation and covalent binding as part of the criteria to progress new chemical entities into development. It also presents examples of drugs with ADRs that are known to form reactive intermediates.
59. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, Ookawara T, Suzuki K, Honke K, Taniguchi N: Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem (2003) 384(4):567-574.
60. Liu ZC, Uetrecht JP: Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to cells. J Pharmacol Exp Ther 275(3): 1476-1483.
61. Manyike PT, Kharasch ED, Kalhom TF, Slattery JT: Contribution of CYP2E1 and CYP3A4 to acetaminophen reactive metabolite formation. Clin Pharmacol Ther (2000) 67(3):275-282.
62. Tada M, Yokoyama H, Ito O, Ohya H, Ogata T: Evaluation of the hepatic reduction of a nitroxide radical in rats receiving ascorbic acid, glutathione or ascorbic acid oxidase by in vivo electron spin resonance study. J Gastroenterol Hepatol (2004) 19(1):99-105.
63. Madden S, Woolf TF, Pool WF, Park BK: An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol (1993) 46(1):13-20.
64. Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK: Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica (1995) 25(1):103-116.
65. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med (1999) 5(5):582-585.
66. Park BK, Kitteringham NR, Maggs JL, Boocock D, White I, Elsby R, Pirmohamed M: Optimal dose identification: Predicting a safe dose in man from animal studies. Proceedings of the Esteve Foundation Symposium IX, Lloret de Mar, Girona, Spain (2000), International Congress Series 1220:13-25. http://www.elsevier.com/inca/publications/store/6/2/2/3/5/9/
67. White IN: Tamoxifen: Is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab (2003) 4(3):223-239.
68. Tolman KG, Chandramouli J: Hepatotoxicity of the thiazolidinediones. Clin Liver Dis (2003) 7(2):369-379.
69. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos (2003)31(4):439-446.